Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases. By delivering chemotherapy agents directly to the tumor site, TACE can maximize local drug concentrations and reduce systemic adverse reactions. Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor. It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A). The application of Bevacizumab during TACE has not been reported. In this study, we will evaluate the the overall survival (OS)、

Trial Details

NCT ID
NCT06311851
Phase
PHASE1 / PHASE2
Sponsor
Pardis Noor Medical Imaging and Cancer Center
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Bevacizumab
Locations (sample)
  • Tehran, Tehran Province, Iran|35.69439,51.42151

Key Eligibility Criteria

  • Confirmation of metastatic liver cancer via histological examination or a characteristic imaging profile on dynamic computed tomography (CT) scan o…
  • Eastern cooperative oncology group performance status (ECOGPS) of 0 or 1
  • Liver function categorized as Child-Pugh class A or B
  • Stable non-hepatic metastases, such as skeletal, pulmonary, or lymph node metastases

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →